Details of the Drug Combinations

General Information of This Drug (ID: DMT1OZ6)

Drug Name

MK-2206 DMT1OZ6

Synonyms

MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;

Indication

Disease Entry	ICD 11	Status	REF
Rectal adenocarcinoma	2B92	Phase 2	[1]
Nasopharyngeal carcinoma	2B6B	Investigative	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

870 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Belinostat + MK-2206	DCJE5WF	Belinostat	Embryonal rhabdomyosarcoma (Cell Line: RD)	[3]
BGJ398 + MK-2206	DCYMFI4	BGJ398	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[3]
BGJ398 + MK-2206	DCY8VM1	BGJ398	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[3]
BGJ398 + MK-2206	DC2QISK	BGJ398	Embryonal rhabdomyosarcoma (Cell Line: RD)	[3]
BMS-754807 + MK-2206	DC1PXTK	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: SMS-CTR)	[4]
BMS-754807 + MK-2206	DC1DPUT	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
BMS-754807 + MK-2206	DC441HM	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
Ceritinib + MK-2206	DCQPSJ6	Ceritinib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[3]
Cyclophosphamide + MK-2206	DC7MMDQ	Cyclophosphamide	Adenocarcinoma (Cell Line: HCT116)	[4]
Cyclophosphamide + MK-2206	DCFMVY0	Cyclophosphamide	Malignant melanoma (Cell Line: A375)	[4]
Cyclophosphamide + MK-2206	DCLVZN6	Cyclophosphamide	Malignant melanoma (Cell Line: SKMEL30)	[4]
Cyclophosphamide + MK-2206	DCLP3XA	Cyclophosphamide	Breast carcinoma (Cell Line: KPL1)	[5]
Cyclophosphamide + MK-2206	DCPO1W1	Cyclophosphamide	Colon carcinoma (Cell Line: RKO)	[5]
Dexamethasone + MK-2206	DCTX4N9	Dexamethasone	Breast carcinoma (Cell Line: KPL1)	[5]
Dexamethasone + MK-2206	DCY02L5	Dexamethasone	Carcinoma (Cell Line: OV90)	[5]
Dexamethasone + MK-2206	DCKCQ3X	Dexamethasone	Colon adenocarcinoma (Cell Line: LOVO)	[5]
Dexamethasone + MK-2206	DC0EA1U	Dexamethasone	Adenocarcinoma (Cell Line: CAOV3)	[3]
Dexamethasone + MK-2206	DCSN65F	Dexamethasone	Adenocarcinoma (Cell Line: NCIH2122)	[3]
Dexamethasone + MK-2206	DCT7LHO	Dexamethasone	Adenocarcinoma (Cell Line: DLD1)	[3]
Dexamethasone + MK-2206	DCJCNU0	Dexamethasone	Adenocarcinoma (Cell Line: HCT116)	[3]
Dexamethasone + MK-2206	DCRIMCR	Dexamethasone	Germ cell tumour (Cell Line: PA1)	[3]
Dexamethasone + MK-2206	DCEADKP	Dexamethasone	Malignant melanoma (Cell Line: A375)	[3]
Dexamethasone + MK-2206	DCMOB37	Dexamethasone	Malignant melanoma (Cell Line: SKMEL30)	[3]
Dexamethasone + MK-2206	DCE03E8	Dexamethasone	Non small cell carcinoma (Cell Line: SKMES1)	[3]
Dexamethasone + MK-2206	DCG8PIH	Dexamethasone	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
Doxorubicin + MK-2206	DCF0N64	Doxorubicin	Adenocarcinoma (Cell Line: A427)	[4]
Doxorubicin + MK-2206	DC1BCDA	Doxorubicin	Adenocarcinoma (Cell Line: NCIH1650)	[4]
Doxorubicin + MK-2206	DC41SZ3	Doxorubicin	Adenocarcinoma (Cell Line: NCIH2122)	[4]
Doxorubicin + MK-2206	DCXEBXO	Doxorubicin	Adenocarcinoma (Cell Line: NCIH23)	[4]
Doxorubicin + MK-2206	DCY1TI9	Doxorubicin	Adenocarcinoma (Cell Line: COLO320DM)	[4]
Doxorubicin + MK-2206	DCOYPEI	Doxorubicin	Adenocarcinoma (Cell Line: HT29)	[4]
Doxorubicin + MK-2206	DCR4WA1	Doxorubicin	Germ cell tumour (Cell Line: PA1)	[4]
Doxorubicin + MK-2206	DCNNII9	Doxorubicin	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Doxorubicin + MK-2206	DCFQU9I	Doxorubicin	Malignant melanoma (Cell Line: RPMI7951)	[4]
Doxorubicin + MK-2206	DCNA0DR	Doxorubicin	Mesothelioma (Cell Line: MSTO)	[4]
Doxorubicin + MK-2206	DCFTRBB	Doxorubicin	Non small cell carcinoma (Cell Line: SKMES1)	[4]
Doxorubicin + MK-2206	DC4CK76	Doxorubicin	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
Doxorubicin + MK-2206	DC30IYX	Doxorubicin	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Doxorubicin + MK-2206	DCG3QXK	Doxorubicin	Prostate carcinoma (Cell Line: LNCAP)	[4]
Doxorubicin + MK-2206	DCFN442	Doxorubicin	Prostate carcinoma (Cell Line: VCAP)	[4]
Doxorubicin + MK-2206	DCOVF0J	Doxorubicin	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Doxorubicin + MK-2206	DCCNRTQ	Doxorubicin	Breast carcinoma (Cell Line: KPL1)	[5]
Doxorubicin + MK-2206	DC2I0ZU	Doxorubicin	Breast carcinoma (Cell Line: OCUBM)	[5]
Doxorubicin + MK-2206	DC23DK1	Doxorubicin	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
Estramustine + MK-2206	DCTDFON	Estramustine	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
Estramustine + MK-2206	DCCD4HU	Estramustine	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
Estramustine + MK-2206	DCG8OD9	Estramustine	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Estramustine + MK-2206	DC1ILR3	Estramustine	Carcinoma (Cell Line: MDAMB436)	[5]
Estramustine + MK-2206	DC42RQI	Estramustine	Colon carcinoma (Cell Line: RKO)	[5]
Estramustine + MK-2206	DCJK8Q2	Estramustine	Adenocarcinoma (Cell Line: CAOV3)	[3]
Estramustine + MK-2206	DCWKQPN	Estramustine	Adenocarcinoma (Cell Line: A427)	[3]
Estramustine + MK-2206	DCY6YVA	Estramustine	Adenocarcinoma (Cell Line: HCT116)	[3]
Estramustine + MK-2206	DCW4WHS	Estramustine	Adenocarcinoma (Cell Line: HT29)	[3]
Estramustine + MK-2206	DCB9TCN	Estramustine	Adenocarcinoma (Cell Line: SW-620)	[3]
Estramustine + MK-2206	DC2QJTT	Estramustine	Amelanotic melanoma (Cell Line: A2058)	[3]
Estramustine + MK-2206	DCQ3LJY	Estramustine	Germ cell tumour (Cell Line: PA1)	[3]
Estramustine + MK-2206	DC5BFHA	Estramustine	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
Estramustine + MK-2206	DCF1QQ0	Estramustine	Malignant melanoma (Cell Line: A375)	[3]
Estramustine + MK-2206	DC6ULTO	Estramustine	Malignant melanoma (Cell Line: HT144)	[3]
Estramustine + MK-2206	DCYR7D4	Estramustine	Malignant melanoma (Cell Line: RPMI7951)	[3]
Estramustine + MK-2206	DCD96Y6	Estramustine	Malignant melanoma (Cell Line: SKMEL30)	[3]
Estramustine + MK-2206	DCH9ZH2	Estramustine	Malignant melanoma (Cell Line: UACC62)	[3]
Estramustine + MK-2206	DCIJJ1U	Estramustine	Mesothelioma (Cell Line: MSTO)	[3]
Estramustine + MK-2206	DCT74DR	Estramustine	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
Etoposide + MK-2206	DC8EQSU	Etoposide	Adenocarcinoma (Cell Line: CAOV3)	[4]
Etoposide + MK-2206	DC6JGMK	Etoposide	Adenocarcinoma (Cell Line: A427)	[4]
Etoposide + MK-2206	DCUKA8H	Etoposide	Adenocarcinoma (Cell Line: NCIH1650)	[4]
Etoposide + MK-2206	DCAN8JX	Etoposide	Adenocarcinoma (Cell Line: NCIH2122)	[4]
Etoposide + MK-2206	DCALRA9	Etoposide	Adenocarcinoma (Cell Line: NCIH520)	[4]
Etoposide + MK-2206	DC6ZPPM	Etoposide	Adenocarcinoma (Cell Line: COLO320DM)	[4]
Etoposide + MK-2206	DCIKPGM	Etoposide	Adenocarcinoma (Cell Line: HCT116)	[4]
Etoposide + MK-2206	DCRSR2C	Etoposide	Adenocarcinoma (Cell Line: HT29)	[4]
Etoposide + MK-2206	DCN44PF	Etoposide	Amelanotic melanoma (Cell Line: A2058)	[4]
Etoposide + MK-2206	DC4C133	Etoposide	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
Etoposide + MK-2206	DCLLK3A	Etoposide	Germ cell tumour (Cell Line: PA1)	[4]
Etoposide + MK-2206	DCSZ8OK	Etoposide	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Etoposide + MK-2206	DC375FU	Etoposide	Malignant melanoma (Cell Line: HT144)	[4]
Etoposide + MK-2206	DCLZB9R	Etoposide	Malignant melanoma (Cell Line: RPMI7951)	[4]
Etoposide + MK-2206	DC5CLGR	Etoposide	Malignant melanoma (Cell Line: SKMEL30)	[4]
Etoposide + MK-2206	DCR5UGT	Etoposide	Malignant melanoma (Cell Line: UACC62)	[4]
Etoposide + MK-2206	DCA0PBQ	Etoposide	Mesothelioma (Cell Line: MSTO)	[4]
Etoposide + MK-2206	DCRF3Q1	Etoposide	Non small cell carcinoma (Cell Line: SKMES1)	[4]
Etoposide + MK-2206	DC9G65A	Etoposide	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
Etoposide + MK-2206	DCQK074	Etoposide	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Etoposide + MK-2206	DC1N0ZM	Etoposide	Prostate carcinoma (Cell Line: LNCAP)	[4]
Etoposide + MK-2206	DCY5EJN	Etoposide	Prostate carcinoma (Cell Line: VCAP)	[4]
Etoposide + MK-2206	DCNIYJU	Etoposide	Breast carcinoma (Cell Line: KPL1)	[5]
Etoposide + MK-2206	DCLALNT	Etoposide	Breast carcinoma (Cell Line: OCUBM)	[5]
Etoposide + MK-2206	DCXU2X9	Etoposide	Carcinoma (Cell Line: OV90)	[5]
Etoposide + MK-2206	DCL6W44	Etoposide	Carcinoma (Cell Line: MDAMB436)	[5]
Etoposide + MK-2206	DC53OD0	Etoposide	Colon carcinoma (Cell Line: RKO)	[5]
Etoposide + MK-2206	DCDH1XN	Etoposide	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
Etoposide + MK-2206	DCKSJVK	Etoposide	Rectal adenocarcinoma (Cell Line: SW837)	[5]
Everolimus + MK-2206	DCLNVPB	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
Everolimus + MK-2206	DC8FVGN	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
Fluorouracil + MK-2206	DC20KMI	Fluorouracil	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
Fluorouracil + MK-2206	DCBN8GW	Fluorouracil	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Fluorouracil + MK-2206	DC5RLZZ	Fluorouracil	Breast carcinoma (Cell Line: OCUBM)	[5]
Fluorouracil + MK-2206	DCA5Y90	Fluorouracil	Carcinoma (Cell Line: OV90)	[5]
Fluorouracil + MK-2206	DCWXNMA	Fluorouracil	Carcinoma (Cell Line: MDAMB436)	[5]
Fluorouracil + MK-2206	DCKYPZD	Fluorouracil	Colon adenocarcinoma (Cell Line: LOVO)	[5]
Fluorouracil + MK-2206	DC3G0Y5	Fluorouracil	Colon carcinoma (Cell Line: RKO)	[5]
Fluorouracil + MK-2206	DC13WV0	Fluorouracil	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
Fluorouracil + MK-2206	DCBPUXA	Fluorouracil	Rectal adenocarcinoma (Cell Line: SW837)	[5]
Fluorouracil + MK-2206	DC0I8DG	Fluorouracil	Adenocarcinoma (Cell Line: CAOV3)	[3]
Fluorouracil + MK-2206	DC0KWKG	Fluorouracil	Adenocarcinoma (Cell Line: OVCAR3)	[3]
Fluorouracil + MK-2206	DCJCQM2	Fluorouracil	Adenocarcinoma (Cell Line: A427)	[3]
Fluorouracil + MK-2206	DCN9WRO	Fluorouracil	Adenocarcinoma (Cell Line: NCIH1650)	[3]
Fluorouracil + MK-2206	DCMXC3E	Fluorouracil	Adenocarcinoma (Cell Line: NCIH2122)	[3]
Fluorouracil + MK-2206	DC633P7	Fluorouracil	Adenocarcinoma (Cell Line: NCIH23)	[3]
Fluorouracil + MK-2206	DCLJ2W7	Fluorouracil	Adenocarcinoma (Cell Line: NCIH520)	[3]
Fluorouracil + MK-2206	DCXXULC	Fluorouracil	Adenocarcinoma (Cell Line: COLO320DM)	[3]
Fluorouracil + MK-2206	DCH3QKJ	Fluorouracil	Adenocarcinoma (Cell Line: DLD1)	[3]
Fluorouracil + MK-2206	DCMTF3U	Fluorouracil	Adenocarcinoma (Cell Line: HCT116)	[3]
Fluorouracil + MK-2206	DCR45E7	Fluorouracil	Adenocarcinoma (Cell Line: HT29)	[3]
Fluorouracil + MK-2206	DCDFKU4	Fluorouracil	Adenocarcinoma (Cell Line: SW-620)	[3]
Fluorouracil + MK-2206	DC3MNK5	Fluorouracil	Amelanotic melanoma (Cell Line: A2058)	[3]
Fluorouracil + MK-2206	DCD0A69	Fluorouracil	Germ cell tumour (Cell Line: PA1)	[3]
Fluorouracil + MK-2206	DCRGFBL	Fluorouracil	Malignant melanoma (Cell Line: A375)	[3]
Fluorouracil + MK-2206	DCO2LUU	Fluorouracil	Malignant melanoma (Cell Line: HT144)	[3]
Fluorouracil + MK-2206	DCYIN0N	Fluorouracil	Malignant melanoma (Cell Line: RPMI7951)	[3]
Fluorouracil + MK-2206	DCCPCMI	Fluorouracil	Malignant melanoma (Cell Line: SKMEL30)	[3]
Fluorouracil + MK-2206	DCQV0W9	Fluorouracil	Malignant melanoma (Cell Line: UACC62)	[3]
Fluorouracil + MK-2206	DCYJSSX	Fluorouracil	Mesothelioma (Cell Line: MSTO)	[3]
Fluorouracil + MK-2206	DCTEETI	Fluorouracil	Non small cell carcinoma (Cell Line: SKMES1)	[3]
Fluorouracil + MK-2206	DCXXOGQ	Fluorouracil	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
Fluorouracil + MK-2206	DCYT3GM	Fluorouracil	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
Fluorouracil + MK-2206	DCKRQ3L	Fluorouracil	Prostate carcinoma (Cell Line: LNCAP)	[3]
Fluorouracil + MK-2206	DCRT2ZU	Fluorouracil	Prostate carcinoma (Cell Line: VCAP)	[3]
Gemcitabine + MK-2206	DC7QG7G	Gemcitabine	Adenocarcinoma (Cell Line: CAOV3)	[4]
Gemcitabine + MK-2206	DCOLOC8	Gemcitabine	Adenocarcinoma (Cell Line: A427)	[4]
Gemcitabine + MK-2206	DC6OSVF	Gemcitabine	Adenocarcinoma (Cell Line: NCIH2122)	[4]
Gemcitabine + MK-2206	DCVNLWT	Gemcitabine	Adenocarcinoma (Cell Line: NCIH520)	[4]
Gemcitabine + MK-2206	DCZ9LSZ	Gemcitabine	Adenocarcinoma (Cell Line: COLO320DM)	[4]
Gemcitabine + MK-2206	DCUA1HB	Gemcitabine	Adenocarcinoma (Cell Line: DLD1)	[4]
Gemcitabine + MK-2206	DCJ37TA	Gemcitabine	Adenocarcinoma (Cell Line: HT29)	[4]
Gemcitabine + MK-2206	DCIUG4I	Gemcitabine	Amelanotic melanoma (Cell Line: A2058)	[4]
Gemcitabine + MK-2206	DCPSN36	Gemcitabine	Germ cell tumour (Cell Line: PA1)	[4]
Gemcitabine + MK-2206	DC1RE8W	Gemcitabine	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Gemcitabine + MK-2206	DCUFLM8	Gemcitabine	Malignant melanoma (Cell Line: HT144)	[4]
Gemcitabine + MK-2206	DCTJX70	Gemcitabine	Malignant melanoma (Cell Line: RPMI7951)	[4]
Gemcitabine + MK-2206	DC9OA2U	Gemcitabine	Mesothelioma (Cell Line: MSTO)	[4]
Gemcitabine + MK-2206	DCUZQPU	Gemcitabine	Non small cell carcinoma (Cell Line: SKMES1)	[4]
Gemcitabine + MK-2206	DCANSG1	Gemcitabine	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Gemcitabine + MK-2206	DCNZLDF	Gemcitabine	Prostate carcinoma (Cell Line: VCAP)	[4]
Gemcitabine + MK-2206	DC66O4S	Gemcitabine	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
Gemcitabine + MK-2206	DCH9HXV	Gemcitabine	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Gemcitabine + MK-2206	DCTUPR4	Gemcitabine	Breast carcinoma (Cell Line: OCUBM)	[5]
Gemcitabine + MK-2206	DCXYQO8	Gemcitabine	Carcinoma (Cell Line: EFM192B)	[5]
Gemcitabine + MK-2206	DCCWN1J	Gemcitabine	Carcinoma (Cell Line: MDAMB436)	[5]
Gemcitabine + MK-2206	DCRUE7G	Gemcitabine	Colon carcinoma (Cell Line: RKO)	[5]
Gemcitabine + MK-2206	DCCB7TE	Gemcitabine	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
Gemcitabine + MK-2206	DCIV6TH	Gemcitabine	Rectal adenocarcinoma (Cell Line: SW837)	[5]
Idarubicin + MK-2206	DCXWCT1	Idarubicin	Adenocarcinoma (Cell Line: CAOV3)	[3]
Idarubicin + MK-2206	DCWGALF	Idarubicin	Adenocarcinoma (Cell Line: A427)	[3]
Idarubicin + MK-2206	DCZYOC7	Idarubicin	Adenocarcinoma (Cell Line: NCIH2122)	[3]
Idarubicin + MK-2206	DCWLUT3	Idarubicin	Adenocarcinoma (Cell Line: COLO320DM)	[3]
Idarubicin + MK-2206	DCZMHKX	Idarubicin	Adenocarcinoma (Cell Line: SW-620)	[3]
Idarubicin + MK-2206	DCH775J	Idarubicin	Amelanotic melanoma (Cell Line: A2058)	[3]
Idarubicin + MK-2206	DC3AL14	Idarubicin	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
Idarubicin + MK-2206	DCKC8RX	Idarubicin	Malignant melanoma (Cell Line: A375)	[3]
Idarubicin + MK-2206	DCC6N72	Idarubicin	Malignant melanoma (Cell Line: RPMI7951)	[3]
Idarubicin + MK-2206	DCWX89S	Idarubicin	Malignant melanoma (Cell Line: SKMEL30)	[3]
Idarubicin + MK-2206	DCZF6RN	Idarubicin	Malignant melanoma (Cell Line: UACC62)	[3]
Idarubicin + MK-2206	DCVLWWC	Idarubicin	Mesothelioma (Cell Line: MSTO)	[3]
Idarubicin + MK-2206	DCEHZAF	Idarubicin	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
JQ1 + MK-2206	DC2BNQF	JQ1	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
JQ1 + MK-2206	DC6Y2ID	JQ1	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
JQ1 + MK-2206	DC4856K	JQ1	Ewing sarcoma (Cell Line: TC-71)	[4]
Lapatinib + MK-2206	DC3R796	Lapatinib	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
Lapatinib + MK-2206	DCT0I92	Lapatinib	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Lapatinib + MK-2206	DCAYZK0	Lapatinib	Breast carcinoma (Cell Line: ZR751)	[5]
Lapatinib + MK-2206	DC7IBU4	Lapatinib	Breast carcinoma (Cell Line: KPL1)	[5]
Lapatinib + MK-2206	DCSKIAU	Lapatinib	Breast carcinoma (Cell Line: OCUBM)	[5]
Lapatinib + MK-2206	DCP0JBD	Lapatinib	Carcinoma (Cell Line: EFM192B)	[5]
Lapatinib + MK-2206	DCG52ZA	Lapatinib	Colon carcinoma (Cell Line: RKO)	[5]
Lapatinib + MK-2206	DCRMVVH	Lapatinib	Rectal adenocarcinoma (Cell Line: SW837)	[5]
Lapatinib + MK-2206	DC7QF2K	Lapatinib	Adenocarcinoma (Cell Line: CAOV3)	[3]
Lapatinib + MK-2206	DCW5M62	Lapatinib	Adenocarcinoma (Cell Line: OVCAR3)	[3]
Lapatinib + MK-2206	DCP8ZUS	Lapatinib	Adenocarcinoma (Cell Line: NCIH1650)	[3]
Lapatinib + MK-2206	DC9KE08	Lapatinib	Adenocarcinoma (Cell Line: NCIH2122)	[3]
Lapatinib + MK-2206	DC756UX	Lapatinib	Adenocarcinoma (Cell Line: NCIH23)	[3]
Lapatinib + MK-2206	DC4DSH3	Lapatinib	Adenocarcinoma (Cell Line: NCIH520)	[3]
Lapatinib + MK-2206	DC8FGX3	Lapatinib	Adenocarcinoma (Cell Line: COLO320DM)	[3]
Lapatinib + MK-2206	DC02DNR	Lapatinib	Adenocarcinoma (Cell Line: DLD1)	[3]
Lapatinib + MK-2206	DCBNHUK	Lapatinib	Adenocarcinoma (Cell Line: HCT116)	[3]
Lapatinib + MK-2206	DC0RBBL	Lapatinib	Adenocarcinoma (Cell Line: HT29)	[3]
Lapatinib + MK-2206	DCP6STQ	Lapatinib	Adenocarcinoma (Cell Line: SW-620)	[3]
Lapatinib + MK-2206	DCXMDRK	Lapatinib	Amelanotic melanoma (Cell Line: A2058)	[3]
Lapatinib + MK-2206	DCJZG20	Lapatinib	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[3]
Lapatinib + MK-2206	DC1P5B6	Lapatinib	Germ cell tumour (Cell Line: PA1)	[3]
Lapatinib + MK-2206	DC4CHS1	Lapatinib	Malignant melanoma (Cell Line: A375)	[3]
Lapatinib + MK-2206	DCJ3JUF	Lapatinib	Malignant melanoma (Cell Line: HT144)	[3]
Lapatinib + MK-2206	DCHSPRB	Lapatinib	Malignant melanoma (Cell Line: RPMI7951)	[3]
Lapatinib + MK-2206	DCEUHVI	Lapatinib	Malignant melanoma (Cell Line: SKMEL30)	[3]
Lapatinib + MK-2206	DCR0WTW	Lapatinib	Malignant melanoma (Cell Line: UACC62)	[3]
Lapatinib + MK-2206	DCAA2AP	Lapatinib	Mesothelioma (Cell Line: MSTO)	[3]
Lapatinib + MK-2206	DCSMH6T	Lapatinib	Non small cell carcinoma (Cell Line: SKMES1)	[3]
Lapatinib + MK-2206	DCAL8I7	Lapatinib	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
Lapatinib + MK-2206	DCFB2IT	Lapatinib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
Lapatinib + MK-2206	DC5XC2V	Lapatinib	Prostate carcinoma (Cell Line: VCAP)	[3]
Metformin + MK-2206	DCE0TF5	Metformin	Adenocarcinoma (Cell Line: HT29)	[4]
Metformin + MK-2206	DCPMMW1	Metformin	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
Metformin + MK-2206	DCAZPCM	Metformin	Malignant melanoma (Cell Line: A375)	[4]
Metformin + MK-2206	DCJ05B9	Metformin	Malignant melanoma (Cell Line: SKMEL30)	[4]
Metformin + MK-2206	DCVV3DN	Metformin	Breast carcinoma (Cell Line: OCUBM)	[5]
Methotrexate + MK-2206	DCIH26S	Methotrexate	Adenocarcinoma (Cell Line: A427)	[4]
Methotrexate + MK-2206	DCH2SOV	Methotrexate	Adenocarcinoma (Cell Line: NCIH23)	[4]
Methotrexate + MK-2206	DCAVZFM	Methotrexate	Adenocarcinoma (Cell Line: COLO320DM)	[4]
Methotrexate + MK-2206	DC4MJ31	Methotrexate	Amelanotic melanoma (Cell Line: A2058)	[4]
Methotrexate + MK-2206	DCELOTU	Methotrexate	Germ cell tumour (Cell Line: PA1)	[4]
Methotrexate + MK-2206	DCPHSA2	Methotrexate	Malignant melanoma (Cell Line: HT144)	[4]
Methotrexate + MK-2206	DCQBJVK	Methotrexate	Malignant melanoma (Cell Line: SKMEL30)	[4]
Methotrexate + MK-2206	DCVOFG2	Methotrexate	Malignant melanoma (Cell Line: UACC62)	[4]
Methotrexate + MK-2206	DC2D537	Methotrexate	Mesothelioma (Cell Line: MSTO)	[4]
Methotrexate + MK-2206	DCUQDE9	Methotrexate	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
Methotrexate + MK-2206	DCB6HWV	Methotrexate	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Methotrexate + MK-2206	DCRKZ1C	Methotrexate	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
Methotrexate + MK-2206	DCDIEF2	Methotrexate	Carcinoma (Cell Line: EFM192B)	[5]
Methotrexate + MK-2206	DCL7TNI	Methotrexate	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
Methotrexate + MK-2206	DC88BRL	Methotrexate	Rectal adenocarcinoma (Cell Line: SW837)	[5]
Mitomycin + MK-2206	DCN81SM	Mitomycin	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
Mitomycin + MK-2206	DC2FZ1C	Mitomycin	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Mitomycin + MK-2206	DCXG3UA	Mitomycin	Breast carcinoma (Cell Line: KPL1)	[5]
Mitomycin + MK-2206	DCWZZDQ	Mitomycin	Breast carcinoma (Cell Line: OCUBM)	[5]
Mitomycin + MK-2206	DCXZ92M	Mitomycin	Carcinoma (Cell Line: OV90)	[5]
Mitomycin + MK-2206	DCEREJI	Mitomycin	Carcinoma (Cell Line: MDAMB436)	[5]
Mitomycin + MK-2206	DCLGC41	Mitomycin	Colon adenocarcinoma (Cell Line: LOVO)	[5]
Mitomycin + MK-2206	DC8DN2F	Mitomycin	Colon carcinoma (Cell Line: RKO)	[5]
Mitomycin + MK-2206	DC6RKXO	Mitomycin	Rectal adenocarcinoma (Cell Line: SW837)	[5]
Mitomycin + MK-2206	DC31C93	Mitomycin	Adenocarcinoma (Cell Line: A427)	[3]
Mitomycin + MK-2206	DCPPYFV	Mitomycin	Adenocarcinoma (Cell Line: NCIH1650)	[3]
Mitomycin + MK-2206	DCU0QRR	Mitomycin	Adenocarcinoma (Cell Line: NCIH2122)	[3]
Mitomycin + MK-2206	DCXJ990	Mitomycin	Adenocarcinoma (Cell Line: NCIH23)	[3]
Mitomycin + MK-2206	DC6L7D8	Mitomycin	Adenocarcinoma (Cell Line: COLO320DM)	[3]
Mitomycin + MK-2206	DC0VZIX	Mitomycin	Adenocarcinoma (Cell Line: HCT116)	[3]
Mitomycin + MK-2206	DCVE92R	Mitomycin	Adenocarcinoma (Cell Line: HT29)	[3]
Mitomycin + MK-2206	DCDXSA7	Mitomycin	Amelanotic melanoma (Cell Line: A2058)	[3]
Mitomycin + MK-2206	DC0ZOK0	Mitomycin	Germ cell tumour (Cell Line: PA1)	[3]
Mitomycin + MK-2206	DCDGPUI	Mitomycin	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
Mitomycin + MK-2206	DC1LPOS	Mitomycin	Malignant melanoma (Cell Line: HT144)	[3]
Mitomycin + MK-2206	DCTS4N9	Mitomycin	Malignant melanoma (Cell Line: RPMI7951)	[3]
Mitomycin + MK-2206	DCHLQU3	Mitomycin	Malignant melanoma (Cell Line: UACC62)	[3]
Mitomycin + MK-2206	DCBMWMM	Mitomycin	Mesothelioma (Cell Line: MSTO)	[3]
Mitomycin + MK-2206	DC49XY5	Mitomycin	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
Mitomycin + MK-2206	DCCHF40	Mitomycin	Prostate carcinoma (Cell Line: VCAP)	[3]
MK-1775 + MK-2206	DCFC43W	MK-1775	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-1775 + MK-2206	DCCO6X0	MK-1775	Adenocarcinoma (Cell Line: A427)	[4]
MK-1775 + MK-2206	DC7JPOQ	MK-1775	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-1775 + MK-2206	DCPF5PE	MK-1775	Adenocarcinoma (Cell Line: NCIH23)	[4]
MK-1775 + MK-2206	DC369HV	MK-1775	Adenocarcinoma (Cell Line: NCIH520)	[4]
MK-1775 + MK-2206	DC52IWZ	MK-1775	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-1775 + MK-2206	DCQHCN2	MK-1775	Adenocarcinoma (Cell Line: HCT116)	[4]
MK-1775 + MK-2206	DCQJKT4	MK-1775	Adenocarcinoma (Cell Line: HT29)	[4]
MK-1775 + MK-2206	DCYS0LN	MK-1775	Adenocarcinoma (Cell Line: SW-620)	[4]
MK-1775 + MK-2206	DCPZ8QH	MK-1775	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-1775 + MK-2206	DC3JZJ4	MK-1775	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
MK-1775 + MK-2206	DC3R8WO	MK-1775	Germ cell tumour (Cell Line: PA1)	[4]
MK-1775 + MK-2206	DCB8UL3	MK-1775	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-1775 + MK-2206	DCXGS5G	MK-1775	Malignant melanoma (Cell Line: A375)	[4]
MK-1775 + MK-2206	DCI0AK7	MK-1775	Malignant melanoma (Cell Line: RPMI7951)	[4]
MK-1775 + MK-2206	DCAUF9J	MK-1775	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-1775 + MK-2206	DCOP21X	MK-1775	Malignant melanoma (Cell Line: UACC62)	[4]
MK-1775 + MK-2206	DCK8X1R	MK-1775	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-1775 + MK-2206	DCDJCT3	MK-1775	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-1775 + MK-2206	DC9S7QC	MK-1775	Prostate carcinoma (Cell Line: VCAP)	[4]
MK-1775 + MK-2206	DCHT9J8	MK-1775	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-1775 + MK-2206	DC2MXPD	MK-1775	Breast carcinoma (Cell Line: KPL1)	[5]
MK-1775 + MK-2206	DCCFBFL	MK-1775	Breast carcinoma (Cell Line: OCUBM)	[5]
MK-1775 + MK-2206	DCIIOM2	MK-1775	Carcinoma (Cell Line: MDAMB436)	[5]
MK-1775 + MK-2206	DCQ1TMN	MK-1775	Colon carcinoma (Cell Line: RKO)	[5]
MK-1775 + MK-2206	DCY9QLV	MK-1775	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-1775 + MK-2206	DCQ8DJH	MK-1775	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-2206 + Buparlisib	DCUMDDT	Buparlisib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Ruxolitinib	DC5I81T	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]
MK-2206 + PD-0325901	DCZVZ9P	PD-0325901	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-2206 + PD-0325901	DCB22JO	PD-0325901	Adenocarcinoma (Cell Line: OVCAR3)	[4]
MK-2206 + PD-0325901	DCWFQB4	PD-0325901	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + PD-0325901	DCAKRPF	PD-0325901	Adenocarcinoma (Cell Line: NCIH1650)	[4]
MK-2206 + PD-0325901	DCIQZ42	PD-0325901	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + PD-0325901	DCYF3YD	PD-0325901	Adenocarcinoma (Cell Line: NCIH23)	[4]
MK-2206 + PD-0325901	DC4NDC0	PD-0325901	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + PD-0325901	DC4X7RY	PD-0325901	Adenocarcinoma (Cell Line: DLD1)	[4]
MK-2206 + PD-0325901	DCPG3V8	PD-0325901	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + PD-0325901	DCYYWX6	PD-0325901	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + PD-0325901	DCLA14V	PD-0325901	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + PD-0325901	DC3OCBP	PD-0325901	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
MK-2206 + PD-0325901	DC51XGW	PD-0325901	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + PD-0325901	DCPUCRG	PD-0325901	Malignant melanoma (Cell Line: RPMI7951)	[4]
MK-2206 + PD-0325901	DCC6Q3J	PD-0325901	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + PD-0325901	DCLL49C	PD-0325901	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + PD-0325901	DCYE2H2	PD-0325901	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + PD-0325901	DCKEM2B	PD-0325901	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + PD-0325901	DCCUPDI	PD-0325901	Prostate carcinoma (Cell Line: LNCAP)	[4]
MK-2206 + Trametinib	DCLYGZ8	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[4]
MK-2206 + Trametinib	DCJ4851	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
MK-2206 + Trametinib	DCYKNNJ	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
MK-2206 + MK-1775	DC90LHD	MK-1775	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + JQ1	DCBW51D	JQ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + JQ1	DC7FY3J	JQ1	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Carfilzomib	DC8RYOL	Carfilzomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Carfilzomib	DC60TP7	Carfilzomib	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Panobinostat	DCV1211	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Panobinostat	DCSRHL6	Panobinostat	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + RTB101	DCFETFN	RTB101	Adenocarcinoma (Cell Line: OVCAR3)	[4]
MK-2206 + RTB101	DC4KVDN	RTB101	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + RTB101	DCAB40L	RTB101	Adenocarcinoma (Cell Line: NCIH1650)	[4]
MK-2206 + RTB101	DC4NSRE	RTB101	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + RTB101	DCD6SBT	RTB101	Adenocarcinoma (Cell Line: NCIH23)	[4]
MK-2206 + RTB101	DCE19QT	RTB101	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + RTB101	DC7T7DN	RTB101	Adenocarcinoma (Cell Line: HCT116)	[4]
MK-2206 + RTB101	DCDSGVS	RTB101	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + RTB101	DCSANPA	RTB101	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + RTB101	DCNMWRF	RTB101	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + RTB101	DCNH6J2	RTB101	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + RTB101	DC5JP4V	RTB101	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + RTB101	DCRGVC8	RTB101	Malignant melanoma (Cell Line: HT144)	[4]
MK-2206 + RTB101	DCYAJ4Q	RTB101	Malignant melanoma (Cell Line: RPMI7951)	[4]
MK-2206 + RTB101	DCXF5Q2	RTB101	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-2206 + RTB101	DCIHS7F	RTB101	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + RTB101	DCNO56T	RTB101	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + RTB101	DC2TW5C	RTB101	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + RTB101	DCD99YX	RTB101	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + RTB101	DCGCIY5	RTB101	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + RTB101	DC32UPR	RTB101	Prostate carcinoma (Cell Line: LNCAP)	[4]
MK-2206 + RTB101	DC81SV1	RTB101	Prostate carcinoma (Cell Line: VCAP)	[4]
MK-2206 + SCH-900776	DCK98N5	SCH-900776	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-2206 + SCH-900776	DCAUUGZ	SCH-900776	Adenocarcinoma (Cell Line: NCIH23)	[4]
MK-2206 + SCH-900776	DCA065B	SCH-900776	Adenocarcinoma (Cell Line: NCIH520)	[4]
MK-2206 + SCH-900776	DCYAN7T	SCH-900776	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + SCH-900776	DC9F0DX	SCH-900776	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + SCH-900776	DCFG7P7	SCH-900776	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + SCH-900776	DCPF62G	SCH-900776	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + SCH-900776	DCMCNEN	SCH-900776	Malignant melanoma (Cell Line: A375)	[4]
MK-2206 + SCH-900776	DCIH705	SCH-900776	Malignant melanoma (Cell Line: HT144)	[4]
MK-2206 + SCH-900776	DCAS7R5	SCH-900776	Malignant melanoma (Cell Line: RPMI7951)	[4]
MK-2206 + SCH-900776	DC1B2QJ	SCH-900776	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + SCH-900776	DCDZOHV	SCH-900776	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + SCH-900776	DCY2P31	SCH-900776	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + SCH-900776	DCG6WL7	SCH-900776	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + SCH-900776	DCUY405	SCH-900776	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + SCH-900776	DCOVT6P	SCH-900776	Prostate carcinoma (Cell Line: VCAP)	[4]
MK-2206 + AZD8055	DCBUA3G	AZD8055	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Formononetin	DCNZEIH	Formononetin	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Formononetin	DC2JXK7	Formononetin	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
MK-2206 + Gemcitabine	DCJIVV2	Gemcitabine	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Everolimus	DC2BU3S	Everolimus	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + CA4P	DC1ZTB8	CA4P	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + 10-hydroxycamptothecin	DCLZL4L	10-hydroxycamptothecin	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + 10-hydroxycamptothecin	DCTFUP0	10-hydroxycamptothecin	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + 10-hydroxycamptothecin	DCJ20OX	10-hydroxycamptothecin	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + 10-hydroxycamptothecin	DC4SOSF	10-hydroxycamptothecin	Adenocarcinoma (Cell Line: DLD1)	[4]
MK-2206 + 10-hydroxycamptothecin	DCVCGNT	10-hydroxycamptothecin	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + 10-hydroxycamptothecin	DCADA1Y	10-hydroxycamptothecin	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + 10-hydroxycamptothecin	DCF234O	10-hydroxycamptothecin	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
MK-2206 + 10-hydroxycamptothecin	DCTM5N0	10-hydroxycamptothecin	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + 10-hydroxycamptothecin	DCQWUA1	10-hydroxycamptothecin	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + 10-hydroxycamptothecin	DCSYJK0	10-hydroxycamptothecin	Malignant melanoma (Cell Line: HT144)	[4]
MK-2206 + 10-hydroxycamptothecin	DCHGIVM	10-hydroxycamptothecin	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-2206 + 10-hydroxycamptothecin	DCN64MP	10-hydroxycamptothecin	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + 10-hydroxycamptothecin	DC3MOV6	10-hydroxycamptothecin	Malignant melanoma (Cell Line: RPMI7951)	[4]
MK-2206 + 10-hydroxycamptothecin	DC2A41P	10-hydroxycamptothecin	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + 10-hydroxycamptothecin	DCCDRUT	10-hydroxycamptothecin	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + 10-hydroxycamptothecin	DCX8YE0	10-hydroxycamptothecin	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + 10-hydroxycamptothecin	DC7UJYZ	10-hydroxycamptothecin	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + 10-hydroxycamptothecin	DCF9UUB	10-hydroxycamptothecin	Prostate carcinoma (Cell Line: LNCAP)	[4]
MK-2206 + 10-hydroxycamptothecin	DCU8W8Q	10-hydroxycamptothecin	Prostate carcinoma (Cell Line: VCAP)	[4]
MK-2206 + GDC-0084	DCI1WR6	GDC-0084	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + PMID25656651-Compound-5	DCXCC6U	PMID25656651-Compound-5	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Steroid derivative 1	DCFK3CS	Steroid derivative 1	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + SNX-2112	DCBFQUR	SNX-2112	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-2206 + SNX-2112	DCWV1D9	SNX-2112	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + SNX-2112	DCCSU4U	SNX-2112	Adenocarcinoma (Cell Line: NCIH1650)	[4]
MK-2206 + SNX-2112	DCB0W6J	SNX-2112	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + SNX-2112	DCDROV8	SNX-2112	Adenocarcinoma (Cell Line: DLD1)	[4]
MK-2206 + SNX-2112	DCDNV8F	SNX-2112	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + SNX-2112	DCF7SL7	SNX-2112	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + SNX-2112	DCI40S4	SNX-2112	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + SNX-2112	DC5KAPJ	SNX-2112	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-2206 + SNX-2112	DCQP548	SNX-2112	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + SNX-2112	DCJXBVU	SNX-2112	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + SNX-2112	DC2D8NG	SNX-2112	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + SNX-2112	DC0ORDL	SNX-2112	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + SNX-2112	DCJMKX8	SNX-2112	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + SNX-2112	DCNRH0O	SNX-2112	Prostate carcinoma (Cell Line: LNCAP)	[4]
MK-2206 + Exherin	DC83TA1	Exherin	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + AT7519	DCJGM3N	AT7519	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + SCH 727965	DCWDGTF	SCH 727965	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Erlotinib	DCJPLDH	Erlotinib	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-2206 + Erlotinib	DCJB8MD	Erlotinib	Adenocarcinoma (Cell Line: OVCAR3)	[4]
MK-2206 + Erlotinib	DCGXAII	Erlotinib	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + Erlotinib	DCOCWP7	Erlotinib	Adenocarcinoma (Cell Line: NCIH1650)	[4]
MK-2206 + Erlotinib	DCPMTYR	Erlotinib	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + Erlotinib	DC4631E	Erlotinib	Adenocarcinoma (Cell Line: NCIH23)	[4]
MK-2206 + Erlotinib	DCEB0J1	Erlotinib	Adenocarcinoma (Cell Line: NCIH520)	[4]
MK-2206 + Erlotinib	DCPM2QW	Erlotinib	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + Erlotinib	DC0983O	Erlotinib	Adenocarcinoma (Cell Line: DLD1)	[4]
MK-2206 + Erlotinib	DC4IT7X	Erlotinib	Adenocarcinoma (Cell Line: HCT116)	[4]
MK-2206 + Erlotinib	DCW9RYR	Erlotinib	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + Erlotinib	DC34EVG	Erlotinib	Adenocarcinoma (Cell Line: SW-620)	[4]
MK-2206 + Erlotinib	DC81C28	Erlotinib	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + Erlotinib	DCVDI8P	Erlotinib	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
MK-2206 + Erlotinib	DC94AAK	Erlotinib	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + Erlotinib	DCJ15YY	Erlotinib	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + Erlotinib	DCXEPOG	Erlotinib	Malignant melanoma (Cell Line: A375)	[4]
MK-2206 + Erlotinib	DC1JTTT	Erlotinib	Malignant melanoma (Cell Line: HT144)	[4]
MK-2206 + Erlotinib	DC8ZOOL	Erlotinib	Malignant melanoma (Cell Line: RPMI7951)	[4]
MK-2206 + Erlotinib	DCIUMOL	Erlotinib	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-2206 + Erlotinib	DC1VFU2	Erlotinib	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + Erlotinib	DCBMMHW	Erlotinib	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + Erlotinib	DCQT8AB	Erlotinib	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + Erlotinib	DCXSK54	Erlotinib	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + Erlotinib	DCEIB1X	Erlotinib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + Erlotinib	DCYJO35	Erlotinib	Prostate carcinoma (Cell Line: LNCAP)	[4]
MK-2206 + Erlotinib	DCI3FI3	Erlotinib	Prostate carcinoma (Cell Line: VCAP)	[4]
MK-2206 + Palbociclib	DC16NQC	Palbociclib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Docetaxel	DCTGOTV	Docetaxel	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + THAPSIGARGIN	DCADMA4	THAPSIGARGIN	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + THAPSIGARGIN	DCHUE4W	THAPSIGARGIN	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
MK-2206 + Etoposide	DC2ZE9D	Etoposide	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Etoposide	DCJ5P2H	Etoposide	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
MK-2206 + Cotellic	DCLUT9S	Cotellic	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[4]
MK-2206 + Cotellic	DCM9SVR	Cotellic	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
MK-2206 + Cycloheximide	DCTNGZW	Cycloheximide	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Cycloheximide	DC5VAJZ	Cycloheximide	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
MK-2206 + Withaferin A	DCCM5KM	Withaferin A	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + PHA-739358	DCUBO0O	PHA-739358	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Mitomycin	DC9EY3T	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[4]
MK-2206 + Mitomycin	DCZ977D	Mitomycin	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Mitomycin	DC8HD2X	Mitomycin	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
MK-2206 + SNX-5422	DCJRS9U	SNX-5422	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Pelitinib	DCCZMX5	Pelitinib	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Ridaforolimus	DC48CAC	Ridaforolimus	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-2206 + Ridaforolimus	DCZXKTY	Ridaforolimus	Adenocarcinoma (Cell Line: OVCAR3)	[4]
MK-2206 + Ridaforolimus	DCJZV07	Ridaforolimus	Adenocarcinoma (Cell Line: NCIH1650)	[4]
MK-2206 + Ridaforolimus	DCJ7VZE	Ridaforolimus	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + Ridaforolimus	DCLXPYZ	Ridaforolimus	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + Ridaforolimus	DCYDYVJ	Ridaforolimus	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + Ridaforolimus	DCC0HE3	Ridaforolimus	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + Ridaforolimus	DCIY1D4	Ridaforolimus	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + Ridaforolimus	DCRYW61	Ridaforolimus	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + Ridaforolimus	DCP7TU8	Ridaforolimus	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + Ridaforolimus	DC29IMA	Ridaforolimus	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + Ridaforolimus	DCMI7EV	Ridaforolimus	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + Ridaforolimus	DCI7PGA	Ridaforolimus	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + Ridaforolimus	DCAXGLU	Ridaforolimus	Prostate carcinoma (Cell Line: LNCAP)	[4]
MK-2206 + MK-4827	DCSSUSV	MK-4827	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-2206 + MK-4827	DC6NTIW	MK-4827	Adenocarcinoma (Cell Line: OVCAR3)	[4]
MK-2206 + MK-4827	DCUOUSC	MK-4827	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + MK-4827	DCTX7DZ	MK-4827	Adenocarcinoma (Cell Line: NCIH1650)	[4]
MK-2206 + MK-4827	DCXZNOK	MK-4827	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + MK-4827	DCRZWRC	MK-4827	Adenocarcinoma (Cell Line: NCIH23)	[4]
MK-2206 + MK-4827	DCFLUKF	MK-4827	Adenocarcinoma (Cell Line: NCIH520)	[4]
MK-2206 + MK-4827	DCQ5930	MK-4827	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + MK-4827	DC56Y63	MK-4827	Adenocarcinoma (Cell Line: DLD1)	[4]
MK-2206 + MK-4827	DCLRUJV	MK-4827	Adenocarcinoma (Cell Line: HCT116)	[4]
MK-2206 + MK-4827	DC4V7D6	MK-4827	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + MK-4827	DC6PSOL	MK-4827	Adenocarcinoma (Cell Line: SW-620)	[4]
MK-2206 + MK-4827	DCLKM9B	MK-4827	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + MK-4827	DCLU5O8	MK-4827	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
MK-2206 + MK-4827	DC0E0CB	MK-4827	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + MK-4827	DCMJ6NE	MK-4827	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + MK-4827	DCVFCWU	MK-4827	Malignant melanoma (Cell Line: A375)	[4]
MK-2206 + MK-4827	DC9IDR0	MK-4827	Malignant melanoma (Cell Line: HT144)	[4]
MK-2206 + MK-4827	DCB7NCC	MK-4827	Malignant melanoma (Cell Line: RPMI7951)	[4]
MK-2206 + MK-4827	DCSPTQ5	MK-4827	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-2206 + MK-4827	DC9FVKQ	MK-4827	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + MK-4827	DCGZD4Z	MK-4827	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + MK-4827	DCJBWKJ	MK-4827	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + MK-4827	DC26H0N	MK-4827	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + MK-4827	DC41BAX	MK-4827	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + MK-4827	DC2RD92	MK-4827	Prostate carcinoma (Cell Line: LNCAP)	[4]
MK-2206 + MK-4827	DCN3MHL	MK-4827	Prostate carcinoma (Cell Line: VCAP)	[4]
MK-2206 + ONC201	DCEQ7W8	ONC201	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Lomustine	DC4QFN8	Lomustine	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + Lomustine	DCTJLH7	Lomustine	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + Lomustine	DCPVAWX	Lomustine	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + Lomustine	DCJHRYM	Lomustine	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + ABT-263	DCKMHR7	ABT-263	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Bortezomib	DC41UO2	Bortezomib	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-2206 + Bortezomib	DC86BWE	Bortezomib	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + Bortezomib	DCKLO65	Bortezomib	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + Bortezomib	DCAHG6J	Bortezomib	Adenocarcinoma (Cell Line: NCIH23)	[4]
MK-2206 + Bortezomib	DCZ3HNJ	Bortezomib	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + Bortezomib	DCQTQTB	Bortezomib	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + Bortezomib	DCD0ZHW	Bortezomib	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + Bortezomib	DCTT52B	Bortezomib	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + Bortezomib	DCX3P0K	Bortezomib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + Bortezomib	DCFBHCN	Bortezomib	Prostate carcinoma (Cell Line: LNCAP)	[4]
MK-2206 + Mebendazole	DCBJVJS	Mebendazole	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Bardoxolone methyl	DC148H3	Bardoxolone methyl	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Bardoxolone methyl	DC4LR26	Bardoxolone methyl	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
MK-2206 + CF102	DC3BKWJ	CF102	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + GSK525762	DC7VY89	GSK525762	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-2206 + GSK525762	DC1JPYV	GSK525762	Malignant melanoma (Cell Line: A375)	[4]
MK-2206 + GSK525762	DCSHZ7C	GSK525762	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-2206 + GSK525762	DCO9587	GSK525762	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + BMS-754807	DCYH6XO	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + (-)-englerin A	DCA74UX	(-)-englerin A	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Decitabine	DCH1AHD	Decitabine	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Sorafenib	DCANQGJ	Sorafenib	Adenocarcinoma (Cell Line: CAOV3)	[4]
MK-2206 + Sorafenib	DC3RYYU	Sorafenib	Adenocarcinoma (Cell Line: OVCAR3)	[4]
MK-2206 + Sorafenib	DC5KK0G	Sorafenib	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + Sorafenib	DCL8H0W	Sorafenib	Adenocarcinoma (Cell Line: NCIH1650)	[4]
MK-2206 + Sorafenib	DC3N9N0	Sorafenib	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + Sorafenib	DCLKY00	Sorafenib	Adenocarcinoma (Cell Line: NCIH23)	[4]
MK-2206 + Sorafenib	DCBI6JQ	Sorafenib	Adenocarcinoma (Cell Line: NCIH520)	[4]
MK-2206 + Sorafenib	DC51TOX	Sorafenib	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + Sorafenib	DC5P51S	Sorafenib	Adenocarcinoma (Cell Line: DLD1)	[4]
MK-2206 + Sorafenib	DCKV3TL	Sorafenib	Adenocarcinoma (Cell Line: HCT116)	[4]
MK-2206 + Sorafenib	DCNQZ6J	Sorafenib	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + Sorafenib	DCICSLS	Sorafenib	Adenocarcinoma (Cell Line: SW-620)	[4]
MK-2206 + Sorafenib	DC89LDE	Sorafenib	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + Sorafenib	DC39DE2	Sorafenib	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
MK-2206 + Sorafenib	DCC1TMT	Sorafenib	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + Sorafenib	DCS58TS	Sorafenib	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + Sorafenib	DCA9X0X	Sorafenib	Malignant melanoma (Cell Line: A375)	[4]
MK-2206 + Sorafenib	DCL1JZ3	Sorafenib	Malignant melanoma (Cell Line: HT144)	[4]
MK-2206 + Sorafenib	DCQC497	Sorafenib	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-2206 + Sorafenib	DCAUNBR	Sorafenib	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + Sorafenib	DC6DFTK	Sorafenib	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + Sorafenib	DCJYIES	Sorafenib	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + Sorafenib	DCT3YMX	Sorafenib	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + Sorafenib	DCNBWJS	Sorafenib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + Sorafenib	DCE4GL3	Sorafenib	Prostate carcinoma (Cell Line: VCAP)	[4]
MK-2206 + PF-562271	DC8C23A	PF-562271	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + PF-562271	DC2X9Q8	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[4]
MK-2206 + PF-562271	DC87DB0	PF-562271	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
MK-2206 + Afatinib	DCW4ARR	Afatinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + NVP-AUY922	DCCZCVB	NVP-AUY922	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + THZ1	DCK2K3X	THZ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Mitotane	DC3BFP4	Mitotane	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Doxorubicin	DCE1TSM	Doxorubicin	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Vorinostat	DCB8LB8	Vorinostat	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + Vorinostat	DCXN5UW	Vorinostat	Adenocarcinoma (Cell Line: NCIH1650)	[4]
MK-2206 + Vorinostat	DCPJORZ	Vorinostat	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + Vorinostat	DCFFDYO	Vorinostat	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + Vorinostat	DCPB6ZR	Vorinostat	Adenocarcinoma (Cell Line: HCT116)	[4]
MK-2206 + Vorinostat	DCYGDQ5	Vorinostat	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + Vorinostat	DCFDNXE	Vorinostat	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + Vorinostat	DCZD8K8	Vorinostat	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + Vorinostat	DCKIYP4	Vorinostat	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + Vorinostat	DCMKMM7	Vorinostat	Malignant melanoma (Cell Line: RPMI7951)	[4]
MK-2206 + Vorinostat	DC06HPW	Vorinostat	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-2206 + Vorinostat	DCR89W6	Vorinostat	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + Vorinostat	DCRURKU	Vorinostat	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + Vorinostat	DCTZX79	Vorinostat	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + Vorinostat	DCS3RIL	Vorinostat	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + Vorinostat	DCOEZPT	Vorinostat	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + Vorinostat	DC021WS	Vorinostat	Prostate carcinoma (Cell Line: VCAP)	[4]
MK-2206 + Ibrutinib	DCKXOGA	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[4]
MK-2206 + Dasatinib	DCAWFVY	Dasatinib	Adenocarcinoma (Cell Line: A427)	[4]
MK-2206 + Dasatinib	DCYJM5A	Dasatinib	Adenocarcinoma (Cell Line: NCIH1650)	[4]
MK-2206 + Dasatinib	DC5FLF7	Dasatinib	Adenocarcinoma (Cell Line: NCIH2122)	[4]
MK-2206 + Dasatinib	DC928TJ	Dasatinib	Adenocarcinoma (Cell Line: NCIH23)	[4]
MK-2206 + Dasatinib	DCTO8H9	Dasatinib	Adenocarcinoma (Cell Line: COLO320DM)	[4]
MK-2206 + Dasatinib	DCHVEXL	Dasatinib	Adenocarcinoma (Cell Line: DLD1)	[4]
MK-2206 + Dasatinib	DCG125Y	Dasatinib	Adenocarcinoma (Cell Line: HCT116)	[4]
MK-2206 + Dasatinib	DCPE0CP	Dasatinib	Adenocarcinoma (Cell Line: HT29)	[4]
MK-2206 + Dasatinib	DCQ0DTR	Dasatinib	Adenocarcinoma (Cell Line: SW-620)	[4]
MK-2206 + Dasatinib	DCBIB4Q	Dasatinib	Amelanotic melanoma (Cell Line: A2058)	[4]
MK-2206 + Dasatinib	DCTJWNV	Dasatinib	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
MK-2206 + Dasatinib	DCOAIIM	Dasatinib	Germ cell tumour (Cell Line: PA1)	[4]
MK-2206 + Dasatinib	DC0TNZ5	Dasatinib	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
MK-2206 + Dasatinib	DCTTM22	Dasatinib	Malignant melanoma (Cell Line: A375)	[4]
MK-2206 + Dasatinib	DC16HZJ	Dasatinib	Malignant melanoma (Cell Line: HT144)	[4]
MK-2206 + Dasatinib	DC4X84Z	Dasatinib	Malignant melanoma (Cell Line: SKMEL30)	[4]
MK-2206 + Dasatinib	DCSZR43	Dasatinib	Malignant melanoma (Cell Line: UACC62)	[4]
MK-2206 + Dasatinib	DCM6GNR	Dasatinib	Mesothelioma (Cell Line: MSTO)	[4]
MK-2206 + Dasatinib	DCOULUV	Dasatinib	Non small cell carcinoma (Cell Line: SKMES1)	[4]
MK-2206 + Dasatinib	DC9ZKKF	Dasatinib	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
MK-2206 + Dasatinib	DCI3MDE	Dasatinib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
MK-2206 + Dasatinib	DC9JINO	Dasatinib	Prostate carcinoma (Cell Line: LNCAP)	[4]
MK-2206 + PD-0325901	DCUGL3V	PD-0325901	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + PD-0325901	DCEUWNY	PD-0325901	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-2206 + PD-0325901	DCBUNOQ	PD-0325901	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + PD-0325901	DC0ZJLL	PD-0325901	Carcinoma (Cell Line: OV90)	[5]
MK-2206 + PD-0325901	DCSWMN5	PD-0325901	Carcinoma (Cell Line: EFM192B)	[5]
MK-2206 + PD-0325901	DCLOVO9	PD-0325901	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + PD-0325901	DCGKU9V	PD-0325901	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-2206 + RTB101	DC6F3XI	RTB101	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + RTB101	DCSZ10L	RTB101	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-2206 + RTB101	DCLS9YB	RTB101	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + RTB101	DCC9UXA	RTB101	Breast carcinoma (Cell Line: OCUBM)	[5]
MK-2206 + RTB101	DCK8R0A	RTB101	Carcinoma (Cell Line: OV90)	[5]
MK-2206 + RTB101	DC362AB	RTB101	Carcinoma (Cell Line: EFM192B)	[5]
MK-2206 + RTB101	DC3126A	RTB101	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + RTB101	DC8SB7C	RTB101	Colon carcinoma (Cell Line: RKO)	[5]
MK-2206 + RTB101	DC20UVO	RTB101	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + RTB101	DCNVYMR	RTB101	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-2206 + SCH-900776	DCP4CVK	SCH-900776	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + SCH-900776	DCAA1QS	SCH-900776	Carcinoma (Cell Line: OV90)	[5]
MK-2206 + SCH-900776	DC1P21L	SCH-900776	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + SCH-900776	DC3KEN4	SCH-900776	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-2206 + 10-hydroxycamptothecin	DCLCL34	10-hydroxycamptothecin	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + 10-hydroxycamptothecin	DC57IE4	10-hydroxycamptothecin	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-2206 + 10-hydroxycamptothecin	DC3HCW9	10-hydroxycamptothecin	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + 10-hydroxycamptothecin	DCN4DCA	10-hydroxycamptothecin	Breast carcinoma (Cell Line: OCUBM)	[5]
MK-2206 + 10-hydroxycamptothecin	DCLVP7G	10-hydroxycamptothecin	Carcinoma (Cell Line: OV90)	[5]
MK-2206 + 10-hydroxycamptothecin	DCTQRCO	10-hydroxycamptothecin	Carcinoma (Cell Line: EFM192B)	[5]
MK-2206 + 10-hydroxycamptothecin	DCP5BJ3	10-hydroxycamptothecin	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + 10-hydroxycamptothecin	DCM2FII	10-hydroxycamptothecin	Colon adenocarcinoma (Cell Line: LOVO)	[5]
MK-2206 + 10-hydroxycamptothecin	DCLEQFW	10-hydroxycamptothecin	Colon carcinoma (Cell Line: RKO)	[5]
MK-2206 + 10-hydroxycamptothecin	DCGI4CV	10-hydroxycamptothecin	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + SNX-2112	DCW1X9R	SNX-2112	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + SNX-2112	DCWB37O	SNX-2112	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-2206 + SNX-2112	DC9350T	SNX-2112	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + SNX-2112	DCFXQ0T	SNX-2112	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + SNX-2112	DC2LTA6	SNX-2112	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-2206 + Erlotinib	DC6VW52	Erlotinib	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + Erlotinib	DCIPQGO	Erlotinib	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-2206 + Erlotinib	DCAO7P7	Erlotinib	Breast carcinoma (Cell Line: ZR751)	[5]
MK-2206 + Erlotinib	DC59C9R	Erlotinib	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + Erlotinib	DCHPRV2	Erlotinib	Breast carcinoma (Cell Line: OCUBM)	[5]
MK-2206 + Erlotinib	DCOQAG9	Erlotinib	Carcinoma (Cell Line: OV90)	[5]
MK-2206 + Erlotinib	DCUXMSD	Erlotinib	Carcinoma (Cell Line: EFM192B)	[5]
MK-2206 + Erlotinib	DCGFZ9N	Erlotinib	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + Erlotinib	DCCTDIE	Erlotinib	Colon carcinoma (Cell Line: RKO)	[5]
MK-2206 + Erlotinib	DCVJTJK	Erlotinib	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-2206 + Ridaforolimus	DC6WQZ4	Ridaforolimus	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + Ridaforolimus	DCQUG4C	Ridaforolimus	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + Ridaforolimus	DC9Q5VX	Ridaforolimus	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + Ridaforolimus	DCOEZ7I	Ridaforolimus	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + MK-4827	DCFG80X	MK-4827	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + MK-4827	DCPS202	MK-4827	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + MK-4827	DCADZ15	MK-4827	Breast carcinoma (Cell Line: OCUBM)	[5]
MK-2206 + MK-4827	DCY2WT1	MK-4827	Carcinoma (Cell Line: OV90)	[5]
MK-2206 + MK-4827	DCEQC76	MK-4827	Carcinoma (Cell Line: EFM192B)	[5]
MK-2206 + MK-4827	DCGHF2G	MK-4827	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + MK-4827	DCA6YBG	MK-4827	Colon adenocarcinoma (Cell Line: LOVO)	[5]
MK-2206 + MK-4827	DCFLCNU	MK-4827	Colon carcinoma (Cell Line: RKO)	[5]
MK-2206 + MK-4827	DCBWQD3	MK-4827	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + Bortezomib	DC50KU0	Bortezomib	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-2206 + Bortezomib	DCXFISR	Bortezomib	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + Bortezomib	DC47QAM	Bortezomib	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-2206 + GSK525762	DCOW5C5	GSK525762	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + GSK525762	DCUT2AW	GSK525762	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-2206 + GSK525762	DCUP9PM	GSK525762	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + GSK525762	DCCTZ8X	GSK525762	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + Sorafenib	DCQXNV2	Sorafenib	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + Sorafenib	DC5A4SM	Sorafenib	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-2206 + Sorafenib	DCDFPZ4	Sorafenib	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + Sorafenib	DC1GFJR	Sorafenib	Breast carcinoma (Cell Line: OCUBM)	[5]
MK-2206 + Sorafenib	DCADJAL	Sorafenib	Carcinoma (Cell Line: OV90)	[5]
MK-2206 + Sorafenib	DCL0Z7F	Sorafenib	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + Sorafenib	DCISVZJ	Sorafenib	Colon carcinoma (Cell Line: RKO)	[5]
MK-2206 + Sorafenib	DC0YYVS	Sorafenib	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + Sorafenib	DC8GSHI	Sorafenib	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-2206 + Vorinostat	DCL1JBR	Vorinostat	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-2206 + Vorinostat	DCPFMBR	Vorinostat	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + Vorinostat	DCIC7RA	Vorinostat	Carcinoma (Cell Line: OV90)	[5]
MK-2206 + Vorinostat	DCU5WAS	Vorinostat	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + Vorinostat	DCBK977	Vorinostat	Colon adenocarcinoma (Cell Line: LOVO)	[5]
MK-2206 + Vorinostat	DCRR4D9	Vorinostat	Colon carcinoma (Cell Line: RKO)	[5]
MK-2206 + Vorinostat	DCTUGNN	Vorinostat	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + Vorinostat	DC3USAG	Vorinostat	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-2206 + Dasatinib	DCSZQAV	Dasatinib	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-2206 + Dasatinib	DCIJONC	Dasatinib	Breast carcinoma (Cell Line: KPL1)	[5]
MK-2206 + Dasatinib	DC4A2UK	Dasatinib	Breast carcinoma (Cell Line: OCUBM)	[5]
MK-2206 + Dasatinib	DC23X31	Dasatinib	Carcinoma (Cell Line: OV90)	[5]
MK-2206 + Dasatinib	DCF05UM	Dasatinib	Carcinoma (Cell Line: EFM192B)	[5]
MK-2206 + Dasatinib	DCWYYIL	Dasatinib	Carcinoma (Cell Line: MDAMB436)	[5]
MK-2206 + Dasatinib	DCKGU6P	Dasatinib	Colon carcinoma (Cell Line: RKO)	[5]
MK-2206 + Dasatinib	DCEZ0SU	Dasatinib	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
MK-2206 + Dasatinib	DCS772R	Dasatinib	Rectal adenocarcinoma (Cell Line: SW837)	[5]
MK-5108 + MK-2206	DCEMWQ4	MK-5108	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
MK-5108 + MK-2206	DC25KX3	MK-5108	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
MK-5108 + MK-2206	DCPAM01	MK-5108	Breast carcinoma (Cell Line: ZR751)	[5]
MK-5108 + MK-2206	DCF9TP5	MK-5108	Breast carcinoma (Cell Line: KPL1)	[5]
MK-5108 + MK-2206	DCH619Q	MK-5108	Breast carcinoma (Cell Line: OCUBM)	[5]
MK-5108 + MK-2206	DCY265F	MK-5108	Adenocarcinoma (Cell Line: CAOV3)	[3]
MK-5108 + MK-2206	DCWHZAE	MK-5108	Adenocarcinoma (Cell Line: NCIH2122)	[3]
MK-5108 + MK-2206	DCY1299	MK-5108	Adenocarcinoma (Cell Line: COLO320DM)	[3]
MK-5108 + MK-2206	DCFKX03	MK-5108	Adenocarcinoma (Cell Line: HCT116)	[3]
MK-5108 + MK-2206	DC2SRZJ	MK-5108	Adenocarcinoma (Cell Line: HT29)	[3]
MK-5108 + MK-2206	DCK1BZ6	MK-5108	Amelanotic melanoma (Cell Line: A2058)	[3]
MK-5108 + MK-2206	DCLRBK8	MK-5108	Germ cell tumour (Cell Line: PA1)	[3]
MK-5108 + MK-2206	DCAS0BF	MK-5108	Malignant melanoma (Cell Line: A375)	[3]
MK-5108 + MK-2206	DCA845T	MK-5108	Malignant melanoma (Cell Line: UACC62)	[3]
MK-5108 + MK-2206	DCODM2O	MK-5108	Mesothelioma (Cell Line: MSTO)	[3]
MK-5108 + MK-2206	DCYA4FR	MK-5108	Non small cell carcinoma (Cell Line: SKMES1)	[3]
MK-5108 + MK-2206	DCY0TYT	MK-5108	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
MK-5108 + MK-2206	DCI7MAO	MK-5108	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
MK-5108 + MK-2206	DCABKON	MK-5108	Prostate carcinoma (Cell Line: VCAP)	[3]
Nintedanib + MK-2206	DCWTMVU	Nintedanib	Ewing sarcoma (Cell Line: TC-71)	[4]
Nintedanib + MK-2206	DCPUSE1	Nintedanib	Hodgkin lymphoma (Cell Line: U-HO1)	[3]
PD-0325901 + MK-2206	DC6ED9P	PD-0325901	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
PD-0325901 + MK-2206	DCNQ1T8	PD-0325901	Breast carcinoma (Cell Line: KPL1)	[5]
PD-0325901 + MK-2206	DCGL1QF	PD-0325901	Breast carcinoma (Cell Line: OCUBM)	[5]
PD-0325901 + MK-2206	DCPW344	PD-0325901	Carcinoma (Cell Line: OV90)	[5]
PD-0325901 + MK-2206	DCQROCU	PD-0325901	Carcinoma (Cell Line: EFM192B)	[5]
PD-0325901 + MK-2206	DCYHVE4	PD-0325901	Carcinoma (Cell Line: MDAMB436)	[5]
PD-0325901 + MK-2206	DCIQZ0R	PD-0325901	Colon carcinoma (Cell Line: RKO)	[5]
PD-0325901 + MK-2206	DC1LZNS	PD-0325901	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
PD-0325901 + MK-2206	DC69JPT	PD-0325901	Rectal adenocarcinoma (Cell Line: SW837)	[5]
PD-0325901 + MK-2206	DC7UTM2	PD-0325901	Adenocarcinoma (Cell Line: OVCAR3)	[3]
PD-0325901 + MK-2206	DCFWLG9	PD-0325901	Adenocarcinoma (Cell Line: A427)	[3]
PD-0325901 + MK-2206	DCLHADZ	PD-0325901	Adenocarcinoma (Cell Line: NCIH1650)	[3]
PD-0325901 + MK-2206	DCDI39N	PD-0325901	Adenocarcinoma (Cell Line: NCIH2122)	[3]
PD-0325901 + MK-2206	DCNG2LD	PD-0325901	Adenocarcinoma (Cell Line: NCIH520)	[3]
PD-0325901 + MK-2206	DCLWN16	PD-0325901	Adenocarcinoma (Cell Line: NCIH23)	[3]
PD-0325901 + MK-2206	DCAMEBC	PD-0325901	Adenocarcinoma (Cell Line: COLO320DM)	[3]
PD-0325901 + MK-2206	DCR6BA2	PD-0325901	Adenocarcinoma (Cell Line: DLD1)	[3]
PD-0325901 + MK-2206	DCH56PU	PD-0325901	Adenocarcinoma (Cell Line: HT29)	[3]
PD-0325901 + MK-2206	DC4ZF58	PD-0325901	Amelanotic melanoma (Cell Line: A2058)	[3]
PD-0325901 + MK-2206	DCI0R4X	PD-0325901	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
PD-0325901 + MK-2206	DCL7I0X	PD-0325901	Malignant melanoma (Cell Line: RPMI7951)	[3]
PD-0325901 + MK-2206	DC8URF5	PD-0325901	Malignant melanoma (Cell Line: UACC62)	[3]
PD-0325901 + MK-2206	DCR3YSO	PD-0325901	Mesothelioma (Cell Line: MSTO)	[3]
PD-0325901 + MK-2206	DCZ8EPL	PD-0325901	Non small cell carcinoma (Cell Line: SKMES1)	[3]
PD-0325901 + MK-2206	DCYSXLR	PD-0325901	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
PD-0325901 + MK-2206	DC4UPC5	PD-0325901	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
PD-0325901 + MK-2206	DCJUY1E	PD-0325901	Prostate carcinoma (Cell Line: VCAP)	[3]
PD-0325901 + MK-2206	DC5LJRR	PD-0325901	Prostate carcinoma (Cell Line: LNCAP)	[3]
PF-562271 + MK-2206	DC3DD9Z	PF-562271	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
PF-562271 + MK-2206	DC4P9AN	PF-562271	Embryonal rhabdomyosarcoma (Cell Line: RD)	[4]
PF-562271 + MK-2206	DCAN7KC	PF-562271	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
PMID25656651-Compound-5 + MK-2206	DCUYW1J	PMID25656651-Compound-5	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[3]
PMID28460551-Compound-2 + MK-2206	DCZ0LFZ	PMID28460551-Compound-2	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
PMID28460551-Compound-2 + MK-2206	DCU5OG4	PMID28460551-Compound-2	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
PMID28460551-Compound-2 + MK-2206	DC8KHWW	PMID28460551-Compound-2	Breast carcinoma (Cell Line: KPL1)	[5]
PMID28460551-Compound-2 + MK-2206	DCKQVB2	PMID28460551-Compound-2	Breast carcinoma (Cell Line: OCUBM)	[5]
PMID28460551-Compound-2 + MK-2206	DCU9Z3G	PMID28460551-Compound-2	Carcinoma (Cell Line: OV90)	[5]
PMID28460551-Compound-2 + MK-2206	DCQIUTI	PMID28460551-Compound-2	Carcinoma (Cell Line: EFM192B)	[5]
PMID28460551-Compound-2 + MK-2206	DCHFMBB	PMID28460551-Compound-2	Carcinoma (Cell Line: MDAMB436)	[5]
PMID28460551-Compound-2 + MK-2206	DCXGWFZ	PMID28460551-Compound-2	Colon adenocarcinoma (Cell Line: LOVO)	[5]
PMID28460551-Compound-2 + MK-2206	DC4YVWR	PMID28460551-Compound-2	Colon carcinoma (Cell Line: RKO)	[5]
PMID28460551-Compound-2 + MK-2206	DCONOH9	PMID28460551-Compound-2	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
PMID28460551-Compound-2 + MK-2206	DCQHK3S	PMID28460551-Compound-2	Rectal adenocarcinoma (Cell Line: SW837)	[5]
PMID28460551-Compound-2 + MK-2206	DCZZW9S	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: CAOV3)	[3]
PMID28460551-Compound-2 + MK-2206	DCF7663	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: OVCAR3)	[3]
PMID28460551-Compound-2 + MK-2206	DCARI41	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: NCIH1650)	[3]
PMID28460551-Compound-2 + MK-2206	DCE4TQF	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: NCIH2122)	[3]
PMID28460551-Compound-2 + MK-2206	DCIWZ4X	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: NCIH520)	[3]
PMID28460551-Compound-2 + MK-2206	DCW65F7	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: COLO320DM)	[3]
PMID28460551-Compound-2 + MK-2206	DC9WQT3	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: DLD1)	[3]
PMID28460551-Compound-2 + MK-2206	DCY2VA5	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: HT29)	[3]
PMID28460551-Compound-2 + MK-2206	DC0PTHN	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: SW-620)	[3]
PMID28460551-Compound-2 + MK-2206	DC4AV5V	PMID28460551-Compound-2	Amelanotic melanoma (Cell Line: A2058)	[3]
PMID28460551-Compound-2 + MK-2206	DCL48TT	PMID28460551-Compound-2	Germ cell tumour (Cell Line: PA1)	[3]
PMID28460551-Compound-2 + MK-2206	DCE4472	PMID28460551-Compound-2	Malignant melanoma (Cell Line: RPMI7951)	[3]
PMID28460551-Compound-2 + MK-2206	DCQ6LJ2	PMID28460551-Compound-2	Malignant melanoma (Cell Line: UACC62)	[3]
PMID28460551-Compound-2 + MK-2206	DCXH2F8	PMID28460551-Compound-2	Mesothelioma (Cell Line: MSTO)	[3]
PMID28460551-Compound-2 + MK-2206	DCT6ME8	PMID28460551-Compound-2	Non small cell carcinoma (Cell Line: SKMES1)	[3]
PMID28460551-Compound-2 + MK-2206	DCRMZZT	PMID28460551-Compound-2	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
PMID28460551-Compound-2 + MK-2206	DCUO2D0	PMID28460551-Compound-2	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
PMID28460551-Compound-2 + MK-2206	DCP68PR	PMID28460551-Compound-2	Prostate carcinoma (Cell Line: LNCAP)	[3]
PMID28460551-Compound-2 + MK-2206	DC3ZDR2	PMID28460551-Compound-2	Prostate carcinoma (Cell Line: VCAP)	[3]
SCH 727965 + MK-2206	DCMRY0I	SCH 727965	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[4]
SCH 727965 + MK-2206	DCOH8VM	SCH 727965	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
SCH 727965 + MK-2206	DC7MCBZ	SCH 727965	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
SCH 727965 + MK-2206	DCWSSCS	SCH 727965	Breast carcinoma (Cell Line: ZR751)	[5]
SCH 727965 + MK-2206	DCPJ3OG	SCH 727965	Breast carcinoma (Cell Line: KPL1)	[5]
SCH 727965 + MK-2206	DCOHNUZ	SCH 727965	Carcinoma (Cell Line: MDAMB436)	[5]
SCH 727965 + MK-2206	DC7A2G3	SCH 727965	Colon adenocarcinoma (Cell Line: LOVO)	[5]
SCH 727965 + MK-2206	DCTQC52	SCH 727965	Colon carcinoma (Cell Line: RKO)	[5]
SCH 727965 + MK-2206	DCHGWUP	SCH 727965	Invasive ductal carcinoma (Cell Line: T-47D)	[5]
SCH 727965 + MK-2206	DCUUUJ6	SCH 727965	Rectal adenocarcinoma (Cell Line: SW837)	[5]
SCH 727965 + MK-2206	DCNPW8U	SCH 727965	Adenocarcinoma (Cell Line: CAOV3)	[3]
SCH 727965 + MK-2206	DC56YTG	SCH 727965	Adenocarcinoma (Cell Line: A427)	[3]
SCH 727965 + MK-2206	DCUGO62	SCH 727965	Adenocarcinoma (Cell Line: NCIH1650)	[3]
SCH 727965 + MK-2206	DCYDBUS	SCH 727965	Adenocarcinoma (Cell Line: NCIH2122)	[3]
SCH 727965 + MK-2206	DC6AW92	SCH 727965	Adenocarcinoma (Cell Line: NCIH23)	[3]
SCH 727965 + MK-2206	DCDSZ42	SCH 727965	Adenocarcinoma (Cell Line: NCIH520)	[3]
SCH 727965 + MK-2206	DCL6JWO	SCH 727965	Adenocarcinoma (Cell Line: COLO320DM)	[3]
SCH 727965 + MK-2206	DCQ6LRR	SCH 727965	Adenocarcinoma (Cell Line: DLD1)	[3]
SCH 727965 + MK-2206	DCD42TG	SCH 727965	Adenocarcinoma (Cell Line: HCT116)	[3]
SCH 727965 + MK-2206	DCT14BL	SCH 727965	Adenocarcinoma (Cell Line: HT29)	[3]
SCH 727965 + MK-2206	DCCNI9P	SCH 727965	Amelanotic melanoma (Cell Line: A2058)	[3]
SCH 727965 + MK-2206	DCC43XJ	SCH 727965	Germ cell tumour (Cell Line: PA1)	[3]
SCH 727965 + MK-2206	DCJUW32	SCH 727965	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
SCH 727965 + MK-2206	DC7OC4J	SCH 727965	Malignant melanoma (Cell Line: A375)	[3]
SCH 727965 + MK-2206	DCI3ME4	SCH 727965	Malignant melanoma (Cell Line: HT144)	[3]
SCH 727965 + MK-2206	DCJK4ZK	SCH 727965	Malignant melanoma (Cell Line: RPMI7951)	[3]
SCH 727965 + MK-2206	DCLOREQ	SCH 727965	Malignant melanoma (Cell Line: SKMEL30)	[3]
SCH 727965 + MK-2206	DCHU4T8	SCH 727965	Malignant melanoma (Cell Line: UACC62)	[3]
SCH 727965 + MK-2206	DCCVKHI	SCH 727965	Mesothelioma (Cell Line: MSTO)	[3]
SCH 727965 + MK-2206	DCRZ595	SCH 727965	Non small cell carcinoma (Cell Line: SKMES1)	[3]
SCH 727965 + MK-2206	DCVV6L2	SCH 727965	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
SCH 727965 + MK-2206	DCUEBAO	SCH 727965	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
SCH 727965 + MK-2206	DCK5AQU	SCH 727965	Prostate carcinoma (Cell Line: LNCAP)	[3]
SCH 727965 + MK-2206	DCELEML	SCH 727965	Prostate carcinoma (Cell Line: VCAP)	[3]
SCH772984 + MK-2206	DCTDYR2	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[3]
SCH772984 + MK-2206	DCYVENI	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[3]
SCH772984 + MK-2206	DCGQHI7	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: RD)	[3]
Taxol + MK-2206	DCFWXTH	Taxol	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
Taxol + MK-2206	DCPCV4D	Taxol	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Taxol + MK-2206	DCB62J1	Taxol	Breast carcinoma (Cell Line: OCUBM)	[5]
Taxol + MK-2206	DC3R9FT	Taxol	Carcinoma (Cell Line: EFM192B)	[5]
Taxol + MK-2206	DCOD2BL	Taxol	Carcinoma (Cell Line: MDAMB436)	[5]
Taxol + MK-2206	DC64ZXE	Taxol	Colon carcinoma (Cell Line: RKO)	[5]
Taxol + MK-2206	DC73SRK	Taxol	Adenocarcinoma (Cell Line: CAOV3)	[3]
Taxol + MK-2206	DC1P3ZJ	Taxol	Adenocarcinoma (Cell Line: A427)	[3]
Taxol + MK-2206	DCPRNN5	Taxol	Adenocarcinoma (Cell Line: NCIH1650)	[3]
Taxol + MK-2206	DCLZISZ	Taxol	Adenocarcinoma (Cell Line: NCIH2122)	[3]
Taxol + MK-2206	DC60SO0	Taxol	Adenocarcinoma (Cell Line: NCIH23)	[3]
Taxol + MK-2206	DCO9LA1	Taxol	Adenocarcinoma (Cell Line: NCIH520)	[3]
Taxol + MK-2206	DC27003	Taxol	Adenocarcinoma (Cell Line: COLO320DM)	[3]
Taxol + MK-2206	DCH6DQ7	Taxol	Adenocarcinoma (Cell Line: DLD1)	[3]
Taxol + MK-2206	DC14W6C	Taxol	Adenocarcinoma (Cell Line: HCT116)	[3]
Taxol + MK-2206	DC7L7U5	Taxol	Adenocarcinoma (Cell Line: HT29)	[3]
Taxol + MK-2206	DCAZM5J	Taxol	Adenocarcinoma (Cell Line: SW-620)	[3]
Taxol + MK-2206	DCOQ454	Taxol	Amelanotic melanoma (Cell Line: A2058)	[3]
Taxol + MK-2206	DCXUPS5	Taxol	Germ cell tumour (Cell Line: PA1)	[3]
Taxol + MK-2206	DC8CKMN	Taxol	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
Taxol + MK-2206	DCFZXEW	Taxol	Malignant melanoma (Cell Line: HT144)	[3]
Taxol + MK-2206	DCU3636	Taxol	Malignant melanoma (Cell Line: RPMI7951)	[3]
Taxol + MK-2206	DC7D1DL	Taxol	Malignant melanoma (Cell Line: SKMEL30)	[3]
Taxol + MK-2206	DCO4U0W	Taxol	Mesothelioma (Cell Line: MSTO)	[3]
Taxol + MK-2206	DCVF4DG	Taxol	Non small cell carcinoma (Cell Line: SKMES1)	[3]
Taxol + MK-2206	DCH2R6J	Taxol	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
Taxol + MK-2206	DCVXZOM	Taxol	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
Taxol + MK-2206	DCX2VXT	Taxol	Prostate carcinoma (Cell Line: VCAP)	[3]
Topotecan + MK-2206	DC1CO3X	Topotecan	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
Topotecan + MK-2206	DCAL1IK	Topotecan	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Topotecan + MK-2206	DCDXGKV	Topotecan	Carcinoma (Cell Line: EFM192B)	[5]
Topotecan + MK-2206	DCLQH29	Topotecan	Colon carcinoma (Cell Line: RKO)	[5]
Topotecan + MK-2206	DC5D6RM	Topotecan	Adenocarcinoma (Cell Line: CAOV3)	[3]
Topotecan + MK-2206	DCNAVCI	Topotecan	Adenocarcinoma (Cell Line: A427)	[3]
Topotecan + MK-2206	DC0XMY0	Topotecan	Adenocarcinoma (Cell Line: NCIH2122)	[3]
Topotecan + MK-2206	DCP2R03	Topotecan	Adenocarcinoma (Cell Line: COLO320DM)	[3]
Topotecan + MK-2206	DCMKSFO	Topotecan	Adenocarcinoma (Cell Line: DLD1)	[3]
Topotecan + MK-2206	DC594EO	Topotecan	Adenocarcinoma (Cell Line: HCT116)	[3]
Topotecan + MK-2206	DC64U2C	Topotecan	Adenocarcinoma (Cell Line: HT29)	[3]
Topotecan + MK-2206	DC1G82Y	Topotecan	Adenocarcinoma (Cell Line: SW-620)	[3]
Topotecan + MK-2206	DC6F4NY	Topotecan	Amelanotic melanoma (Cell Line: A2058)	[3]
Topotecan + MK-2206	DC8OH29	Topotecan	Germ cell tumour (Cell Line: PA1)	[3]
Topotecan + MK-2206	DCKQZHI	Topotecan	Malignant melanoma (Cell Line: SKMEL30)	[3]
Topotecan + MK-2206	DC44EG3	Topotecan	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
Topotecan + MK-2206	DCOL852	Topotecan	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
Vinblastine + MK-2206	DC6T62W	Vinblastine	Adenocarcinoma (Cell Line: CAOV3)	[4]
Vinblastine + MK-2206	DCSC8YB	Vinblastine	Adenocarcinoma (Cell Line: NCIH1650)	[4]
Vinblastine + MK-2206	DCS340J	Vinblastine	Adenocarcinoma (Cell Line: COLO320DM)	[4]
Vinblastine + MK-2206	DCT9ZXJ	Vinblastine	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Vinblastine + MK-2206	DCNHL2T	Vinblastine	Malignant melanoma (Cell Line: HT144)	[4]
Vinblastine + MK-2206	DCZT8V9	Vinblastine	Malignant melanoma (Cell Line: RPMI7951)	[4]
Vinblastine + MK-2206	DC126J3	Vinblastine	Malignant melanoma (Cell Line: UACC62)	[4]
Vinblastine + MK-2206	DCWW7C9	Vinblastine	Mesothelioma (Cell Line: MSTO)	[4]
Vinblastine + MK-2206	DCTT4H6	Vinblastine	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[4]
Vinblastine + MK-2206	DCSK0UP	Vinblastine	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Vinblastine + MK-2206	DC19UB9	Vinblastine	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
Vinblastine + MK-2206	DCPFRY7	Vinblastine	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Vinblastine + MK-2206	DC1ZDK2	Vinblastine	Breast carcinoma (Cell Line: KPL1)	[5]
Vinblastine + MK-2206	DCWRJ2G	Vinblastine	Breast carcinoma (Cell Line: OCUBM)	[5]
Vinblastine + MK-2206	DCNAA3S	Vinblastine	Rectal adenocarcinoma (Cell Line: SW837)	[5]
Vinorelbine + MK-2206	DCXFCPB	Vinorelbine	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[5]
Vinorelbine + MK-2206	DCHHSCV	Vinorelbine	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[5]
Vinorelbine + MK-2206	DCQUH50	Vinorelbine	Breast carcinoma (Cell Line: KPL1)	[5]
Vinorelbine + MK-2206	DC9N7XZ	Vinorelbine	Breast carcinoma (Cell Line: OCUBM)	[5]
Vinorelbine + MK-2206	DC666OK	Vinorelbine	Carcinoma (Cell Line: EFM192B)	[5]
Vinorelbine + MK-2206	DCLL75N	Vinorelbine	Carcinoma (Cell Line: MDAMB436)	[5]
Vinorelbine + MK-2206	DCW93CM	Vinorelbine	Colon carcinoma (Cell Line: RKO)	[5]
Vinorelbine + MK-2206	DCI8YHU	Vinorelbine	Rectal adenocarcinoma (Cell Line: SW837)	[5]
Vinorelbine + MK-2206	DCFBD6M	Vinorelbine	Adenocarcinoma (Cell Line: NCIH1650)	[3]
Vinorelbine + MK-2206	DCLFX4I	Vinorelbine	Adenocarcinoma (Cell Line: NCIH2122)	[3]
Vinorelbine + MK-2206	DCA6KNQ	Vinorelbine	Adenocarcinoma (Cell Line: NCIH23)	[3]
Vinorelbine + MK-2206	DCRF8H2	Vinorelbine	Adenocarcinoma (Cell Line: COLO320DM)	[3]
Vinorelbine + MK-2206	DC7QJSS	Vinorelbine	Adenocarcinoma (Cell Line: DLD1)	[3]
Vinorelbine + MK-2206	DCCWDAY	Vinorelbine	Adenocarcinoma (Cell Line: HCT116)	[3]
Vinorelbine + MK-2206	DCVDUL2	Vinorelbine	Adenocarcinoma (Cell Line: HT29)	[3]
Vinorelbine + MK-2206	DCR6E3Q	Vinorelbine	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[3]
Vinorelbine + MK-2206	DC67KRX	Vinorelbine	Germ cell tumour (Cell Line: PA1)	[3]
Vinorelbine + MK-2206	DCNPEC2	Vinorelbine	Large cell lung carcinoma (Cell Line: NCI-H460)	[3]
Vinorelbine + MK-2206	DCZKEM4	Vinorelbine	Malignant melanoma (Cell Line: RPMI7951)	[3]
Vinorelbine + MK-2206	DC8LJQ4	Vinorelbine	Malignant melanoma (Cell Line: SKMEL30)	[3]
Vinorelbine + MK-2206	DCLMBSA	Vinorelbine	Mesothelioma (Cell Line: MSTO)	[3]
Vinorelbine + MK-2206	DCEMPCB	Vinorelbine	Non small cell carcinoma (Cell Line: SKMES1)	[3]
Vinorelbine + MK-2206	DCP1USN	Vinorelbine	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[3]
Vinorelbine + MK-2206	DCEFP9S	Vinorelbine	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[3]
Vinorelbine + MK-2206	DC1OFV6	Vinorelbine	Prostate carcinoma (Cell Line: LNCAP)	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 870 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7945).
2	UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.